June 2021

Is the 21-Gene Assay Useful in Predicting Endocrine Therapy Response?
With the arrival of precision medicine, the focus is on personalized medicine. A tool that has aided in this effort is the Oncotype DX Recurrence Score, a prognostic and therapeutic decision making multigene panel test intended for use in patients with estrogen receptor-positive, human epidermal growth factor receptor-negative breast cancer. Read more.

Advertisement

Progesterone Receptor-Negative Breast Cancer Predicts Worse Outcome
Eighty percent of breast cancers (BCs) are estrogen receptor-positive (ER+), while only 60% of BCs are progesterone receptor-positive (PR+), with 20% of invasive BCs presenting as mixed hormone receptor status (i.e., with ER+ and PR- disease). Nevertheless the importance of PR-positivity status stimulates much debate. Read more.

Preventing Breast Cancer in High-Risk Patients
It is estimated that one in eight women will develop breast cancer (BC) in her lifetime. While inherited genetic variants are thought to contribute to the development of BC in 5% to 10% of cases, there are many other environmental and lifestyle factors that increase disease risk. For women deemed to be at high risk for developing BC, there is a need for interventions to help prevent disease occurrence. Read more

Connect With U.S. Pharmacist
Facebook Twitter USP Google AppUSP Itunes App
Advertisement